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THE treatment of cancer by the local application of chemical substances has been
practised since the time of Hippocrates. Moore, writing in the British Medical
Journal of 1866, commented on the failure of occasional applications of caustic
pastes in the treatment of cancer and suggested the necessity for a long continued
stream of the medicinal agent flowing through the tumour.
Modern chemotherapy of solid tumours began about 1940 when nitrogen
mustard was first used in the treatment of the reticuloses. Klopp and his colleagues
(1950) first described a method of localised chemotherapy for tumours in an
area with an accessible arterial blood supply. Intermittent injections of nitrogen
mustard given through a small polythene catheter in the appropriate artery
produced regressions of tumour growth which had not been obtained by systemic
chemotherapy. The amount of chemotherapeutic agent given by intra-arterial
injection was limited, because of the general toxic effects produced after the
drug had passed through the tumour circulation.
The ideal agent for this form of treatment would be a substance with a very
short effective life in the body after injection so that the drug was completely
inactivated by the time it had passed through the tumour circulation. This type
of substance has not been produced but research continues along these lines.
Two methods have been developed which aim at increasing the local or regional
cytotoxic effects and at the same time reducing the general toxic actions of the
drugs. The first consists of vascular isolation of the region to be treated with
maintenance of the circulation of the isolated area by a pump oxygenator during
treatment. The second consists of injecting large doses of the drug intra-arterially
and at the same time giving an antagonist to the cytotoxic agent by systemic
injection. The highest concentration of the drug occurs in the treated area and
severe toxicity is avoided.
The majority of chemotherapeutic agents which have been used fall into two
niain groups, the alkylating agents and the antimetabolites. All these substances
produce their biological effects by interfering with nucleic acid synthesis. The
alkylating agents act by direct chemical reaction with the complex nucleic acid
molecules and so destroy their normal function. Antimetabolites, on the other
hand, interfere with the synthesis of nucleic acids by competing with normal
metabolites for enzymes required in nucleic acid production. Alkylating agents
act rapidly and most of them exert their maximum effect within minutes of
coming into contact with body tissues. These drugs are suitable for single
injections or short periods of isolated perfusion.
151The antimetabolites act slowly and it is necessary to have the antimetabolite
in contact with body tissues for many days before the maximal effect is obtained.
These drugs are usually given continuously for days so that the sequentially
dividing cells will be exposed to the antimetabolite. Another miscellaneous group
consists of plant extracts and antibodies. Limited clinical success has been
reported with these substances.
The principal cancer chemotherapeutic agents which are clinically useful in
the treatment of solid tumours are listed in Table 1.
TABLE 1.
EXAMIPLES OF SOME OF THE DRUGS CURRENTLY IN USE FOR
CANCER CHEMOTHERAPY.
ALKYLATING AGENTS:
NITROGEN
MUSTARDS TRIETHYLENEAMINES ANTIMETABOLITES ANTIBIOTICS
Leukeran ... T.E.M. ... 6 Mercaptopurine ... Actinomycin D
(Triethylenemelamine)
Melphalan 5 Fluorouracil ...
(Phenylalanine ... Thiotepa ...
Mustard) Amethopterin ...
Cyclophosphomide ... ... (Methotrexate)
(Endoxan)
Degranol ... ... ...
(Mannomustine)
Myleran
REGIONAL PERFUSION.
Creech and colleagues (1958) first published the results of the treatment of
localised malignant disease by regional arterial perfusion. Since then regional
perfusion has been applied in a variety of ways by many investigators and some
of the results have been encouraging.
Extracorporeal perfusion implies the continuous artificial circulation of cytotoxic
drugs through an isolated area. When the area can be easily isolated as in a limb
the dose of the drug is limited only by the tolerance of the tissues. Where
isolation is difficult a varying amount o;f the drug leaks into the general circulation
and the maximum dose of drug is limited by this spill over into the rest of
the body.
The drug that has produced the most dramatic regressions of tumours after
regional perfusion is melphalan (phenylalanine mustard). This drug is a com-
bination of an alkylating agent with phenylalanine. It is thought that melanin-
forming cells have an affinity for phenylalanine and this explains the selective
toxicity in melanoma.
152Melphalan has been used exclusively in the present studies. Three of the factors
which influence the effectiveness of drug perfusion are temperature, flow rate,
and oxygen tension. The apparatus is designed so that each can be controlled.
The utilization of the drug is related to the temperature of the infusate. A heat
exchange unit is connected between the arterial pump and the patient, and the
infusate delivered at 40°C.
The venous return from the isolated area is pumped through an oxygenating
column and pure oxygen is added. The blood then passes through a defoaming
sponge before reaching the arterial inflow pump. High flow rates of 100-120ml.
per minute are maintained in order to achieve a uniform distribution of blood
in the peripheral tissues and the pressure in the isolated circuit is maintained
below the systemic blood pressure in order to limit the leakage into the general
circulation.
The pump system is primed with 1 litre of heparinized blood and the main
vessels cannulated. A tourniquet is tightened to isolate the part and the pumps
switched on. The first injection of cytotoxic agent is given as soon as the venous
return is adequate. Intermittent doses are injected during perfusion, and the total
amount given depends on the leakage into the general circulation. This is small
in femoral perfusion but higher in forequarter or pelvic perfusion. An estimate
of the leak into the rest of the body is obtained by injecting some of the patient's
red blood cells labelled with radioactive chromium 51 into the isolated part at
the beginning of the perfusion. Samples are taken from a systemic vein at fifteen-
minute intervals during perfusion and the percentage leakage calculated.
CLINICAL ExPERIENCE.
Isolated regional perfusion has been applied to the limbs and girdles in five
patients. The technique has been used by other workers to perfuse the head and
neck, liver and lung, but the enormous leakage in these areas reduces the value
of the method.
Regional chemotherapy has not been used for new cases of peripheral malignant
disease, but has been reserved for cases of locally advanced or recurrent disease.
It has been the aim to use perfusion as an adjuvant to further surgical treatment
where possible. Regional perfusion has been attempted in six patients and was
successfully completed in five. One patient had advanced atheroma and previous
dissection in the groin made arterial cannulation difficult and dangerous, and the
procedure was abandoned. Two patients had prophylactic perfusion after radical
surgery. Four patients had recurrent nmalignant melanomata and one had a
recurring pleomorphic sarcoma. The histories of the individual patients are as
follows:
Case 1. This patient, a man aged 29, attended the Department of Dermatology
in August, 1961, with a pigmented mole in the interscapular region, which had
been present for nine months. A wide excision was carried out and a split skin
graft applied. The pathological report was that of malignant melanoma, and the
extent of the resection appeared adequate. The patient was re-admitted in May,
1962, with a hard mass in the right supraclavicular fossa. This was the only
evidence of spread. Forequarter perfusion was carried out immediately after
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Idissection and removal of the affected neck glands which contained malignant
melanoma. The catheters were threaded into the brachial artery and vein and the
subclavian vessels were occluded in the neck. The perfusion was of 100 mg. of
melphalan. The post-operative course was uneventful for the first week and then
the white cell count fell to less than 1,000 within ten days and remained low for
four days. During this period of marrow depression the wound became infected
and a staphlococcal septicaemia ensued. The organism was resistant to most anti-
biotics and the patient died within a few days from septicemia.
Case 2. This patient, a lady aged 75, had a malignant melanoma locally excised
from the sole of the right foot, in August, 1962. She was seen a few months
later and was found to have enlarged groin glands and local recurrence of tumour.
Isolated regional perfusion lasting one hour was carried out with 80mg. melphalan
and at the same time excision of the groin glands was performed. These glands
contained excessive melanin but no malignant cells. The lesion in the foot
regressed in the first week after treatment. The white cell count fell to 1,200
per cu. mm. by the twelfth day, but soon rose again. The groin wound failed to
heal and became infected. A brisk reactionary haemorrhage occurred from the
femoral artery thirty days after perfusion and femoral ligation was necessary.
The right leg required to be amputated a few days later and the patient died
from bronchopneumonia two months after perfusion.
Case 3. This patient, a man aged 78, had a painful tumour excised from the
sole of the right foot in January, 1963. This was a malignant melanoma and a
local recurrence rapidly developed. He was treated in March, 1963, by a block
dissection of inguinal glands and isolated regional perfusion of the right leg.
80 mg. of melphalan was given during perfusion which lasted one hour. The
local recurrence on the foot was not touched and rapidly regressed after perfusion.
The white cell count fell to 1,500 per cu. mm. within twelve days and soon rose
again to normal limits. The wound healed satisfactorily and convalescence was
uneventful. The patient refused to have a further biopsy and excision at the site
of the local recurrence and the regression has persisted. Without excision of the
site of recurrence it is difficult to know the effectiveness of treatment in this
patient.
Case 4. This patient, a woman aged 34, had an ulcerated mole excised from
the outer aspect of the right leg in February, 1961. This was found histologically
to be a malignant melanoma. Recurrence occurred at the site of excision within
six months and a further wide local excision and skin graft was performed. Three
weeks later a radical block dissection of the groin glands was performed, and the
glands were found to be free of tumour. However, a further local recurrence
was noted one month later. This was a small black nodule at the edge of the
previous skin graft.
The right leg was perfused with 75 mg. of melphalan for a period of 1 hour
20 minutes. The white cell count subsequently fell to 2,000 per cu. mm. and
erythema developed in the perfused limb. The recurrent nodule did not regress
immediately and it was excised two weeks later and found to be an epidermoid
cyst containing organised blood clot. The patient has remained free of recurrence
for two years after excision and perfusion. Regional perfusion in this patient
turned out to have been prophylactic and really should have been done at the
time of regional gland dissection.
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right gluteal region in 1948. This recurred and was again locally excised in
February, 1961, July, 1961, and June, 1962. The histologica[ picture was that
of a pleomorphic sarcoma. A further wide excision of gluteal muscle and scar
tissue was carried out, and the hind quarter was perfused with 80 mg. of melphalan
in July, 1962. The catheters were threaded into the common iliac vessels which
were occluded at their origins during perfusion. The limbs were protected by
femoral cuffs which were inflated during perfusion. The patient had an
uneventful convalescence and has remained free of recurrence for over one year.
Serious complications occurred in two patients. Severe bone marrow depression
occurred in one man due to an excessive leak and in the other patient local healing
was impaired. Tumour response was observed in two patients. The result in the
two patients treated prophylactically is difficult to assses at this stage, but both
are free of tumour at one and two years respectively.
Krementz (1962) reported their experience with 350 perfusions and claimed
that twelve out of forty-five patients with malignant melatnoma remained under
control after two years. Irvine and Noon (1960) have also reported dramatic
regressions of malignant melanomata.
CONTINUOUS INTRA-ARTERIAL INFUSION.
This term is applied to the administration of drugs by an intra-arterial drip.
The drug which is not fixed or inactivated by the tissue in the infused area
returns to the rest of the body by the venous drainage of the part. The folic acid
antagonist methotrexate has been used in this form of treatment. Methotrexate
interferes with the conversion of folic acid to folinic acid which is in turn
necessary for nucleic acid synthesis.
It is possible to combat any methotrexate which enters the circulation by
giving folinic acid systemically, and because of this very large doses of the
antimetabolite can be given into the tumour-bearing area. Maximum concen-
tration of the drug occurs in the infused area and the excess which recirculates
causes little damage because of the circulating folinic acid. Cells vary in their
sensitivity to antimetabolites depending upon the phase of mitosis. A high
concentration of drug must be maintained in the tumour-bearing area for a
prolonged period, so that all the cells will pass through a sensitive phase when
the drug is present.
This treatment is simpler to carry out than regional perfusion and has been
more widely used. Head and neck cancer and advanced pelvic tumours have
been suitable for this form of therapy.
Malignant disease of the head and neck often remains localised and produces
severe pain and disability by local tissue infiltration. Some of the arterial branches
of the external carotid artery are easily entered and it is in the treatment of this
form of malignant disease that the most encouraging results have been obtained.
Sullivan (1962) found that 50 per cent. of patients with advanced head and neck
cancer obtained relief of symptoms, and partial regression of growth after infusion
therapy. Westbury (1962) and Espiner (1962) have had similar experiences. The
155reports of these workers contain a few cases of relatively early disease in which
total regression of tumour occurred after infusion and in sonme cases this has
been maintained for more than one year. These observations of total regression
in a few patieints raises the question of the use of infusion for the treatment of
the early rather than the advanced case.
CLINICAL EXPERIENCE.
Twenty-four patients with epidermoid carcinoma of the head and neck have
been treated in the surgical Professorial Unit, Royal Victoria Hospital. The
disease was unilateral and confined to the distribution of the external carotid
artery in every case. The superficial temporal artery was cannulated in sixteen
patients. The superior thyroid artery was used five times, the facial artery once,
and the external carotid in the remaining two patients. There were no compli-
cations from the minor surgical procedure of cannulation which was always
carried out under general anoesthesia.
It is important that the catheter tip lies in such a position that the infusate
reaches the desired area. A slow injection of 1 - 2 cc. of 5 per cent. fluorescein
solution is given and the area examined under ultraviolet light. The fluorescence
persists in the capillary bed of the irrigated area for about thirty minutes. When
the catheter is in the external carotid supply, fluorescence occurs in the skin of
the face, neck, scalp, and the mucosa of the mouth and tongue. If the infusate
is reaching the internal carotid supply fluorescence occurs in the eye, eyelids,
and forehead. The position of the catheter is adjusted until fluorescence is
observed in the required area. Methotrexate (50 mg.) is dissolved in 500ml. of
physiological saline and placed in a plastic bag containing heparin. The plastic
pack is inserted into the pouch of the Fenwal pressure infusor, which consists
of an air-filled cuff, surrounding the polythene bag. The pressure in the cuff is
kept above the patient's arterial pressure and the drip rate adjusted so that the
contents of the plastic pack are infused slowly over twenty-four hours. The
drip rate and the pressure in the infusion cuff are checked each fifteen minutes
during treatment by the duty nurse. This method of arterial infusion has proved
very satisfactory, and is easier to manage than infusion by the gravity feed or
an arterial pump described by others (Sullivan, 1962; Espiner, 1962). The danger
of air embolism is eliminated. The patient can move freely about the ward
during treatment since the apparatus is very light and can be easily fixed to the
buttonhole of a dressing-gown.
A full blood count is checked daily and the dose of 50 mg. of methotrexate
per day continued until the white cell count falls below 2,000 per cu. mm. or
toxic signs appear. The usual early toxic signs consist of painful mouth ulcers.
Folinic acid (citrovorum factor) is given daily by intramuscular injection (6nmg.
four-hourly). The average duration of infusion in the present series was 5 - 6
days, by which time 250 - 300 mg. of methotrexate had passed through the
growth. The catheter was withdrawn at the end of the treatment and light
pressure applied for five minutes. Blceling from the infusion site did not occur
after withdrawal of the catheter.
156The results of the treatment are shown in Table 2. Total regression was defined
as the comiplete disappearanice of all visible tumour, but without histological
confirmation. This occurred in two patients and has persisted for three and six
moniths respectively. The treatment was considered to have been worthwhile in
the patients who had partial reduction of tumour size and relief of symptoms.
Paini relief was obser\ved bv the seconld day of infusionl anid analgesic requirenments
were reduced. The remissioins didlnot last loniger than 5 - 6 weeks inlmost
instanices which is rather clisappoinltinig. The inicidlenice of tunmour response and(
paini relief w\Nvas greatest in the paticlts wvho clidl not have prior treatmlienlt with
ra(diotherapy. Espinier, Vowles, andl \IValker (1962) record a similar observation.
TABLE 2.
CASI S OF CARCINOMA OF TIIE HFAD AND NECK TREATED WVITH METTIIOTREXATF
AND THOSEI Siiowix1cN RE(GRESSION AND/OR SUBJEICTIVE1 1AMPROVEM\IENT.
NO. PARTIAL TOTAL SUBJECTVE
LESION TRE'ATED REGREISSION RFGRESSION IMPROVEMENT
Carrcinoina:
Tongue - - - 2 ... - ... -
Buccal Mucosa - - - 7 ... 3 ... 1 ... 5
Neck Glands - - - 7 ... 4 ... - ... 3
Skin of Face - - - 2 ... 1 ... 1 ... 2
Sinuses - - - 2 ... 1 ... - ... 1
Malignant Tunmours of
Salivary Glandcis - - 4 ... - ... - ... 1
TOTAL - - 24 ... 9 ... 2 ... 12
The incidence of complications in a palliative procedure is important when
assessing the value of the treatment. Complications occurred in eight patients.
(A reduction in white cell count alone was not counted as a complication.) Very
marked ulceration of the buccal mucosa xvith ordema occurred in two patients.
Onie patient developed a complete hemiplegia during treatment and died. Two
others had transient signs of contralateral hemiplegia which cleared up in 5 - 6
days. The hemiplegia is presumably due to thrombi forming around the catheter
in the external carotid artery and breaking off into the internal carotid circulation.
One patient developed a severe bronchopneumonia during treatment and died.
Severe mental depression was associated with infusion in a further four patients.
Six patients developed a generalised macular skin rash after 4 - 5 days. This was
severe enough to cause the treatment to be discontinued in each case. The
majority of complicatioins occurre(d in patienits xx'ho had hadl previous radiotherapy.
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KThe case histories of the two patients who had a total regression of growth are
as follows:-
Case 6. This patient was a lady aged 57 who was first seen in May, 1962,
complaining of a large solid tumour over the right parotid region. The growth
was widely excised and was found to be a squamous carcinoma. A skin flap was
taken from the forehead to cover the defect, and the bare area on the forehead
was then covered with split skin grafts. The growth recurred six months later
and she was re-admitted with a large recurrent solid tumour at the site of the
previous excision, with no evidence of glandular spread.
A catheter was inserted in the superficial temporal artery and 375 mg. of
methotrexate infused during eight days. The bulk of the tumour became necrotic
within 2 - 3 days and there was a rapid reduction in size. The white cell count
fell to 1,500 per cu. mm. after eight days. The drug was stopped for four days
to allow the white cell count to recover and further 200 mg. of methotrexate
was given. The white cell count fell sharply again and the treatment was stopped.
There was complete regression of the growth after four weeks and there has been
no local recurrence after three months.
Case-7. This was a man aged 74 who complained of a painful ulcer in the
roof of the mouth for four months. This was an ulcerating squamous carcinoma,
one inch in diameter, in the right side of the hard palate. A catheter was placed
in the superficial temporal artery and fluorescence was noted in the margins of
the ulcer. The infusion was continued for one week and a total dose of 350 mg.
of methotrexate was given. The patient was free of pain within a few days of
starting treatment, and the ulcer was half its original size at the end of one week.
Regression continued and after three weeks a course of radiotherapy was
commenced, because the patient had had no previous conventional therapy. The
regression continued and the ulcer healed. The patient has remained vell and
is free of any recurrence nine months later.
DiscussiON.
There is no doubt that regional perfusion and infusion offers a degree of control
over locally advanced malignanit disease, particularly the malignant melanoma.
However, no patient appears to have been cured of advanced disease by these
methods.
There would appear to be reasonable grounds for believing that these new
methods may improve the prognosis in many patients when combined with
current conventional forms of treatment. The existing evidence suggests that if
arterial infusion is being considered then it should be given before and not after
radiotherapy or surgical excision.
There are many fields of future advancement in this subject. For example,
there is no way of knowing whether a tumour will respond to any particular
drug. Some tumours respond dramatically while their exact histological counter-
part in another patient shows no response. Techniques require to be developed
whereby cancer cells obtained at biopsy can be grown in tissue culture and the
sensitivity to various chemotherapeutic agents assesse(l before any treatment is
given.
158The results of combining drugs with different cytotoxic actions appears to be
another fruitful field of investigation anid the inter-relationiships between the
combination of surgical radiotherapeutic and chemothcrapeutic methods rcquires
detailed study. It is also possible that a new type of specialist may enmerge in
the next decadc-thc chemotherapist-oncologist who will advise on the appli-
cation of the advancing knowledge in the treatment of inidividual cases. It is to
be hoped that developments in this field will help to uniitc rather thani separate
the specialist treatment of the cancer patient. The surgeoni, radiotherapist, anld
chenmotherapist should all conmbinie their interest and(i experience so that the
inidividual cancer patient will have the best possible chanice of cure or control
of his disease.
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